Author: Glaucoma Today

An Industry Perspective

Anyone reading Glaucoma Today knows that
some 3 million Americans suffer from this neurodegenerative
disease. Thanks to its size, this
market continues to attract extensive investment
in drug development, which has provided physicians
and the…

INDUSTRY NEWS AND INNOVAT IONS

h4Merck to Acquire Inspire
Pharmaceuticals, Inc./h4
Merck and Co., Inc. (Whitehouse Station, NJ), and Inspire
Pharmaceuticals, Inc. (Raleigh, NC), announced that they
have entered into a definitive agreement under which
Merck will acquire I…

Why Do I Perform Research?

When my 2 1/2-year-old son asks, “Why are
trees green? Why did Mama sneeze? Why
did baby Alex spit up?” I smile. I smile
because I am amazed at how inquisitive
human beings are, even at such a young age. I smile
because others once had th…

The Ganglion Cell Complex

The measurement of the perifoveal ganglion cell
layer recently emerged as a new diagnostic
parameter in glaucoma. Various manufacturers
of spectral-domain optical coherence tomography
(SD-OCT) systems have released or will soon release
softwa…

Word From the Cutting Edge

Early in March 2011, emGlaucoma Today/em held the
third annual Cutting Edge: Innovative Glaucoma
Surgery Symposium. Iqbal Ike Ahmed, MD, and
Richard Lewis, MD, served as the course directors
of this 1-day event that brought together clinic…

The Literature

h4SHORT-TERM REPEATABILITY OF DIURNAL
INTRAOCULAR PRESSURE PATTERNS IN
GLAUCOMATOUS INDIVIDUALSsup1/sup/h4
emRealini T, Weinreb N, Wisniewski S.*br /
Ophthalmology/em, January 2011
strongDo patients treated for primary …